ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Egnyte Unveils Next-Generation Data Governance Solutions for Life Sciences at SCOPE 2026

MOUNTAIN VIEW, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Egnyte, a leader in secure content collaboration, intelligence, and governance, will introduce its newest suite of modern data governance capabilities for life sciences organizations at SCOPE Summit 2026. These advances are designed to help companies move more quickly, collaborate more securely, and stay audit-ready as they advance through clinical and regulatory milestones.

A key addition to Egnyte’s portfolio is a built-in, GxP-validated eSignature solution, fully compliant with 21 CFR Part 11. This secure solution eliminates paper-based delays, strengthens data integrity, and speeds execution by securing the link between signer and document for permanent compliance and faster time-to-market.

Enhancements to Egnyte’s Controlled Documents now feature configurable categories and document statuses, customized to simplify document workflows for complex, dynamic biopharmaceutical needs that demand unquestionable compliance. These configurable options go beyond “Draft” and “Final” statuses to allow alignment with specific standard operating procedures. Custom categories serve as metadata tags that dictate regulatory treatment for thousands of document types. Organizations can efficiently track and manage approvals, reviews, and document types to maintain stronger compliance, reduce risk, and improve operational efficiency across clinical and quality workflows.

“At Egnyte, we understand the stringent requirements on life sciences companies to demonstrate data integrity across every stage of clinical development,” said Abhay Kini, Practice Leader, Life Sciences, Egnyte. “With GxP-validated eSignature and enhanced Controlled Documents, we're giving clinical and quality teams the tools to execute compliant workflows from the convenience of their content platform. This eliminates the gaps and workarounds that create audit risk without compromising the user experience.”

To learn about leveraging Quality by Design to create structured, audit-ready data governance systems throughout the clinical lifecycle, attend “Sifting Through Chaos: Applying a Quality by Design Approach to Data Governance,” presented by Catherine Hall, Global Head of GxP Validation at Egnyte, on Wednesday, February 4, 2026, at 5:10 pm EST.

For more information about Egnyte and its capabilities, visit Egnyte’s booth (#228) at SCOPE 2026 in Orlando, Fla., from February 2 to 5, 2026, or www.egnyte.com/lifesciences.

About Egnyte:

Egnyte combines the power of cloud content management, data security, and AI into one intelligent content platform. More than 23,000 customers trust Egnyte to improve employee productivity, automate business processes, and safeguard critical data, in addition to offering specialized content intelligence and automation solutions across industries, including architecture, engineering, and construction (AEC), life sciences, and financial services. For more information, visit www.egnyte.com.

Media Contact:
Erin Mancini
Head of Public Relations
media@egnyte.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  239.30
-2.43 (-1.01%)
AAPL  259.48
+1.20 (0.46%)
AMD  236.73
-15.45 (-6.13%)
BAC  53.20
+0.12 (0.23%)
GOOG  338.53
-0.13 (-0.04%)
META  716.50
-21.81 (-2.95%)
MSFT  430.29
-3.21 (-0.74%)
NVDA  191.13
-1.38 (-0.72%)
ORCL  164.58
-4.43 (-2.62%)
TSLA  430.41
+13.85 (3.32%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.